Amorfix in-licenses technology for neurodegenerative diseases

By Lisa Kerner

Erie, Pa., Feb. 2 - Amorfix Life Sciences Ltd. said it has obtained an exclusive worldwide license to novel targets on superoxide dismutase-1 (SOD1), which is a protein known to misfold and aggregate in the neurological disease Amyotrophic Lateral Sclerosis (ALS).

The company also obtained an exclusive five-year option to acquire the intellectual property and know how surrounding the licensed technology, according to a company news release.

Amorfix said it will use these novel targets to initiate its therapeutic program for neurodegenerative diseases, beginning with ALS.

ALS belongs to a family of fatal neurodegenerative diseases, which includes Alzheimer's and Parkinson's diseases.

The SOD1 targets were discovered by Dr. Neil Cashman, the company's chief scientific officer, in his former academic laboratory at the University of Toronto. The university assigned all rights to Cashman, who has licensed the technology to Amorfix.

Amorfix will invest a minimum of $300,000 on development of the technology under the terms of the license.

Toronto-based Amorfix is an emerging theranostics company focused on the diagnosis and treatment of neurodegenerative diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.